Germany: BioNTech shutting down COVID vaccine production entirely, 1,860 jobs at risk
Key takeaways
- The German company that pioneered one of the first m RNA coronavirus vaccines is halting production, handing the reins to partner Pfizer.
- The company is winding down its COVID vaccine production entirely, leaving the production to US partner Pfizer going forward.
- "In the course of this year we will produce the last doses here in Germany," a company spokeswoman told the Reuters news agency.
Why this matters: an international story with cross-border implications worth tracking.
The German company that pioneered one of the first m RNA coronavirus vaccines is halting production, handing the reins to partner Pfizer. Bio NTech is restructuring to focus on research and illnesses like cancer.
https://p.dw.com/p/5DJbk Bio NTech made a name for itself during the pandemic as one of the first companies to develop a vaccine for COVID-19Image: Abdulhamid Hoşbaş/Anadolu Agency/IMAGOAdvertisement The Mainz-based company Bio NTech that shot to global notoriety amid the COVID-19 pandemic for its work on one of the first mRNA coronavirus vaccines has announced drastic restructuring plans.
The company is winding down its COVID vaccine production entirely, leaving the production to US partner Pfizer going forward.